Objective  To investigate the relationship of the expression level of long non-coding RNA (LncRNA) SChLAP1 with clinicopathological parameters and clinical prognosis in prostate cancer tissue.

  Methods  The expression levels of LncRNA SChLAP1 in prostate cancer tissues, normal adjacent tissues and benign prostatic hyperplasia tissues were determined by quantitative real-time polymerase chain reaction (qRT-PCR); the relationships between the expression levels of LncRNA SChLAP1 and clinicopathological parameters were analyzed; Kaplan-Meier survival curve was used to analyze the overall survival (OS) and disease-free survival (DFS); Cox risk regression model was used to analyze the risk factors for clinical prognosis of prostate cancer patients.

  Results  Expression level of LncRNA SChLAP1 in prostate cancer tissue was significantly higher than that in adjacent normal tissue and benign prostatic hyperplasia tissue (P < 0.01). The 1-year, 2-year and 3-year disease-free survival rates were 84.69%, 65.31% and 46.94%, respectively, and the overall survival rates were 89.80%, 76.53% and 58.16%, respectively. The expression level of LncRNA SChLAP1 in prostate cancer tissues was correlated with tumor stage, tumor differentiation, lymph node metastasis and Gleason score (P < 0.05), and was not correlated with the patient's age or tumor size (P>0.05). FDS and OS in patients with high expression of LncRNA S ChLAP1 were significantly lower than those in patients with low expression of LncRNA SChLAP1 (P < 0.05). The tumor stage, tumor differentiation, lymph node metastasis, Gleason score and LncRNA SChLAP1 expression were all influential factors of DFS and OS in prostate cancer patients (P < 0.05).

  Conclusion  LncRNA SChLAP1 is highly expressed in prostate cancer tissues and may be related to the occurrence and development of prostate cancer, which can be used as an evaluation index of clinical prognosis of prostate cancer.